Comparison of Time to Next Treatment or Death Between Front‐Line Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) Among Transplant‐Ineligible Patients With Multiple Myeloma

Comparison of Time to Next Treatment or Death Between Front‐Line Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) Among Transplant‐Ineligible Patients With Multiple Myeloma

ABSTRACT Introduction Daratumumab, lenalidomide, and dexamethasone (DRd) and bortezomib, lenalidomide, and dexamethasone (VRd) are the only preferred treatment regimens for patients with transplant‐ineligible (TIE) newly diagnosed multiple myeloma (NDMM). As there are no randomized head‐to‐head stud...

Full description

Bibliographic Details
Main Authors: Doris K. Hansen, Santosh Gautam, Marie‐Hélène Lafeuille, Carmine Rossi, Bronwyn Moore, Anabelle Tardif‐Samson, Philippe Thompson‐Leduc, Alex Z. Fu, Annelore Cortoos, Shuchita Kaila, Rafael Fonseca
Format: Article
Language:English
Published: Wiley 2024-11-01
Series:Cancer Medicine
Subjects:
bortezomib
daratumumab
drug therapy
health care
hematologic diseases
multiple myeloma
Online Access:https://doi.org/10.1002/cam4.70308

Internet

https://doi.org/10.1002/cam4.70308

Similar Items